344 related articles for article (PubMed ID: 37111371)
21. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Adashek JJ; Subbiah V; Kurzrock R
Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
[TBL] [Abstract][Full Text] [Related]
22. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
Yoshino T; Pentheroudakis G; Mishima S; Overman MJ; Yeh KH; Baba E; Naito Y; Calvo F; Saxena A; Chen LT; Takeda M; Cervantes A; Taniguchi H; Yoshida K; Kodera Y; Kitagawa Y; Tabernero J; Burris H; Douillard JY
Ann Oncol; 2020 Jul; 31(7):861-872. PubMed ID: 32272210
[TBL] [Abstract][Full Text] [Related]
23. Tissue-Agnostic Drug Development: A New Path to Drug Approval.
Thein KZ; Lemery SJ; Kummar S
Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971
[TBL] [Abstract][Full Text] [Related]
24. A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.
Mulder J; van Stuijvenberg OC; van Hennik PB; Voest EE; Pasmooij AMG; Stoyanova-Beninska V; de Boer A
Front Med (Lausanne); 2022; 9():893400. PubMed ID: 35775007
[TBL] [Abstract][Full Text] [Related]
25. [Histology-agnostic tumor treatment - a farewell to tumor entities?].
Kerle I; Heining C
Dtsch Med Wochenschr; 2023 Sep; 148(18):1174-1181. PubMed ID: 37657455
[TBL] [Abstract][Full Text] [Related]
26. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
Capper D; Reifenberger G; French PJ; Schweizer L; Weller M; Touat M; Niclou SP; Euskirchen P; Haberler C; Hegi ME; Brandner S; Le Rhun E; Rudà R; Sanson M; Tabatabai G; Sahm F; Wen PY; Wesseling P; Preusser M; van den Bent MJ
Neuro Oncol; 2023 May; 25(5):813-826. PubMed ID: 36632791
[TBL] [Abstract][Full Text] [Related]
27. Histology-agnostic drug development - considering issues beyond the tissue.
Pestana RC; Sen S; Hobbs BP; Hong DS
Nat Rev Clin Oncol; 2020 Sep; 17(9):555-568. PubMed ID: 32528101
[TBL] [Abstract][Full Text] [Related]
28. TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs.
Han SY
Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34209967
[TBL] [Abstract][Full Text] [Related]
29. Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database.
Pestana RC; Serrano C
Front Oncol; 2022; 12():1079909. PubMed ID: 36741731
[TBL] [Abstract][Full Text] [Related]
30. Agnostic drug development revisited.
Hernando-Calvo A; Rossi A; Vieito M; Voest E; Garralda E
Cancer Treat Rev; 2024 Jul; 128():102747. PubMed ID: 38763053
[TBL] [Abstract][Full Text] [Related]
31. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
32. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
33. Profiling of gene fusion involving targetable genes in Chinese gastric cancer.
Liu ZH; Zhu BW; Shi M; Qu YR; He XJ; Yuan HL; Ma J; Li W; Zhao DD; Liu ZC; Wang BM; Wang CY; Tao HQ; Ma TH
World J Gastrointest Oncol; 2022 Aug; 14(8):1528-1539. PubMed ID: 36160735
[TBL] [Abstract][Full Text] [Related]
34. Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.
Bernocchi O; Sirico M; Corona SP; Strina C; Milani M; Cappelletti MR; Ferrero G; Ziglioli N; Cervoni V; Macchiavelli A; Roviello G; Generali D
Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33669326
[TBL] [Abstract][Full Text] [Related]
35. [The application of target-based tissue-agnostic therapy in the treatment of lung cancer].
Peták I
Magy Onkol; 2020 Sep; 64(3):206-215. PubMed ID: 32966351
[TBL] [Abstract][Full Text] [Related]
36. Current Clinical Practice of Precision Medicine Using Comprehensive Genomic Profiling Tests in Biliary Tract Cancer in Japan.
Kanai M
Curr Oncol; 2022 Sep; 29(10):7272-7284. PubMed ID: 36290850
[TBL] [Abstract][Full Text] [Related]
37. Tumor-Agnostic Treatment for Cancer: When How is Better than Where.
Lavacchi D; Roviello G; D'Angelo A
Clin Drug Investig; 2020 Jun; 40(6):519-527. PubMed ID: 32307639
[TBL] [Abstract][Full Text] [Related]
38. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
[No Abstract] [Full Text] [Related]
39. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
40. NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series.
Iannantuono GM; Riondino S; Sganga S; Rosenfeld R; Guerriero S; Carlucci M; Capotondi B; Torino F; Roselli M
J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36579526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]